Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Papillon Study
NCT03391921Phase 4Active, not recruiting
- Sponsor
- Saint-Pierre University Hospital
- Start
- Jan 2018
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Saint-Pierre University Hospital. Primary endpoint: Rate of seroconversion in HPV antibodies against HPV at Month 7. Started Jan 2018; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03391921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391921.